BOCA RATON, Fla., Feb. 11 Biotest PharmaceuticalsCorporation (BPC), a wholly owned subsidiary of Biotest AG, Dreieich, Germany,announced that it has acquired a plasma collection facility located at 2860Cerrillos Road, Santa Fe, New Mexico from Talecris Plasma Resources, Inc.With this acquisition, BPC now operates 11 plasma centers in various locationsthroughout the United States. Last year, the company announced it hadaggressive plans for further expansion during the next two years. BPC willcontinue to explore opportunities to expand its plasma collection operationsto address the global demand for this very important source material.Financial terms of the purchase were not disclosed.
"We are extremely pleased to add the Santa Fe facility to our network ofplasma centers in the U.S.," remarked Dr. Rainer Pabst, Chief ExecutiveOfficer of BPC. "We are looking forward to continuing to build upon ourexisting foundation to reach our goals of continued growth and expanded rangeof top-quality plasma products."
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation develops and manufacturespharmaceutical and biotherapeutic products with a specialization inimmunology. Biotest Pharmaceuticals was formed in 2007 as part of the BiotestAG acquisition of Nabi Pharmaceuticals' Biologics business unit, including itsplasmapheresis centers across the United States. The company employsapproximately 560 people in the U.S. Biotest Pharmaceuticals is a subsidiaryof Biotest AG, a German-based global provider of plasma proteins that employsapproximately 1,850 people worldwide.
To learn more about Biotest Pharmaceuticals and how we help make adifference in the lives of patients and the healthcare community, please visitus at www.biotestpharma.com
About Biotest AG
Biotest AG, Dreieich, Germany, is a company that researches andmanufactures pharmaceutical, biotherapeutic and diagnostic products and hasspecialized in immunology and haematology. In its Pharmaceutical segment,Biotest develops immunoglobulins, clotting factors and albumins based on humanblood plasma. These are used for diseases of the immune system orhaematopoietic system. In the Biotherapeutic segment, Biotest researches intothe clinical development of monoclonal antibodies, including in theindications of rheumatoid arthritis and blood cancer. The Diagnostic segmentspans reagents and immunological diagnostics which are used, for example, inblood transfusions and transplants. Biotest has around 1,950 employeesworldwide and its shares are listed in the Stock Exchange's SDAX on theFrankfurt Stock Exchange.
SOURCE Biotest Pharmaceuticals Corporation